Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving β-blocking agents

Current Cardiology Reports

Volumn 3, Issue 3, 2001, Pages 224-231

  Shakar, Simon F ^b   Bristow, Michael R ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOTONIC AGENT; PHOSPHODIESTERASE INHIBITOR;

ANIMAL; CHRONIC DISEASE; CONGESTIVE HEART FAILURE; DRUG CONTRAINDICATION; HUMAN; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOTONIC AGENTS; CHRONIC DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; PHOSPHODIESTERASE INHIBITORS;

EID: 0035349806     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-001-0027-8     Document Type: Article

References (76)

1. Bristow MR: b-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101:558-569.
2. Packer M, Bristow MR, Cohn JN, et al., for the US Carvedilol Heart Failure Study Group: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349-1355.
3. MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet 1999, 353:2001-2007.
4. CIBIS-II Investigators and Committees: The cardiac insufficiency bisoprolol study II (CIBIS-II). Lancet 1999, 353:9-13.
5. Bristow MR: Mechanism of action of b-blocking agents in heart failure. Am J Cardiol 1997, 80:26L-40L.
6. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996, 94:2807-2816.
7. Krum H, Sackner-Bernstein JD, Goldsmith RL, et al.: Doubleblind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 1995, 92:1499-1506.
8. Macdonald PS, Keogh AM, Aboyoun CL, et al.: Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure. J Am Coll Cardiol 1999, 33:924-931.
9. CIBIS Investigators and Committees: A randomized trial of b-blockade in heart failure: the cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994, 90:1765-1773.
10. Lechat P, Escolano S, Golmard JL, et al.: Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1997, 96:2197-2205.
11. The BEST Trial Investigators: The b-blocker evaluation of Survival Trial. N Engl J Med 2001, in press.
12. Insel PA: Adrenergic receptors: evolving concepts and clinical implications. N Engl J Med 1996, 334:580-585.
13. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in b 1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999, 96:7059-7064.
14. Bisognano JD, Weinberger HD, Bohlmeyer TJ, et al.: Myocardial- directed overexpression of the human b1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000, 32:817-830.
15. Liggett SB, Tepe NM, Lorenz JN, et al.: Early and delayed consequences of b2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2000, 101:1707-1714.
16. Rockman HA, Chien KR, Choi D-J, et al.: Expression of a b-adrenergic receptor kinase I inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998, 95:7000-7005.
17. Freeman K, Iaccarino G, Bohlmeyer T, Leinwand LA: Overexpression of the b2 adrenergic receptor accelerates heart failure in hypertrophic cardiomyopathy mice. Circulation 2000, 100(Suppl I):I493.
18. Mann DL, Kent RL, Parsons B, Cooper G IV: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992, 85:790-804.
19. Communal C, Singh K, Sawyer DB, Colluci WS: Opposing effects of b1- and b2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis-toxin sensitive G protein. Circulation 1999, 100:2210-2212.
20. Ishikawa Y, Homcy CJ: The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res 1997, 80:297-304.
21. Bristow MR, Hershberger RE, Port JD, et al.: b1- and b2- adrenergic receptor mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharm 1989, 35:295-303.
22. Xiao RP, Cheng H, Zhou YY, Kuschel M, Lakatta EG: Recent advances in cardiac b2- adrenergic signal transduction. Circ Res 1999, 85:1092-1100.
23. Rapundalo ST, Solaro RJ, Kranias EG: Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ Res 1989, 64:104-111.
24. Goldspink PH, Russell B: The cAMP response element binding protein is expressed and phosphorylated in cardiac myocytes. Circ Res 1994, 74:1042-1049.
25. Leroy M-J, Degerman E, Taira M, et al.: Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 cells. Biochemistry 1996, 35:10194-10202.
26. Movsesian MA, Smith CJ, Krall J, et al.: Sarcoplasmic reticulum- associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest 1991, 88:15-19.
27. Ludmer PL, Wright RF, Arnold JM, et al.: Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 1986, 73:130-137.
28. Herrmann HC, Ruddy TD, William G, et al.: Inotropic effect of enoximone in patients with severe heart failure: demonstration by left ventricular end-systolic pressure-volume analysis. J Am Coll Cardiol 1987, 9:1117-1123.
29. Monrad ES, McKay RG, Baim DS, et al.: Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984, 70:1030-1037.
30. Binkley PF, Shaffer PB, Ryan JM, Leier CV: Augmentation of diastolic function with phosphodiesterase inhibition in congestive heart failure. J Lab Clin Med 1989, 114:266-271.
31. Edes I, Kiss E, Kitada Y, et al.: Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig hearts. Circ Res 1995, 77:107-113.
32. Gao MH, Lai NC, Roth DM, et al.: Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 1999, 99:1618-1622.
33. Luo W, Grupp IL, Ponniah S, et al.: Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of b-agonist stimulation. Circ Res 1994, 75:401-409.
34. Minamisawa S, Hoshijima M, Chu G, et al.: Chronic phospholamban- sarcoplasmic reticulum ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 1999, 99:313-322.
35. Iwase M, Bishop SP, Uechi M, et al.: Adverse effects of chronic endogenous sympathetic drive induced by cardiac Gsa overexpression. Circ Res 1996, 78:517-524.
36. Bristow MR, Port JD, Kelly RA: Treatment of heart failure. In Heart Disease: A Textbook of Cardiovascular Medicine, edn 6. Edited by Braunwald E. Philadelphia: WB Saunders; 2000.
37. Simpson P: Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha-1 adrenergic response. J Clin Invest 1983, 72:732-738.
38. Pinson A, Schluter KD, Zhou XJ, et al.: Alpha- and b-adrenergic stimulation of protein synthesis in cultured adult ventricular cardiomyocytes. J Mol Cell Cardiol 1993, 25:477-490.
39. Milano CA, Dolber PC, Rockman HA, et al.: Myocardial expression of a constitutively active a1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci U S A 1994, 91:10109-10113.
40. Bristow MR: Changes in myocardial and vascular receptors in heart failure. J Am Coll Cardiol 1993, 22(Suppl A):61A-71A.
41. Ungerer M, Böhm M, Elce JS, et al.: Altered expression of b-adrenergic receptor kinase and b 1-adrenergic receptors in the failing human heart. Circulation 1993, 87:454-463.
42. Fowler MB, Laser JA, Hopkins GL, et al.: Assessment of the b-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986, 74:1290-1302.
43. Colucci WS, Denniss AR, Leatherman GF, et al.: Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. J Clin Invest 1988, 81:1103-1110.
44. White M, Yanowitz F, Gilbert EM, et al.: Role of b-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995, 76:1271-1276.
45. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB: b-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol 1985, 17(Supp 2):41-52.
46. Cohn JN, Coats AJ: Heart failure 99 -the MOXCON story. Int J Cardiol 1999, 71:109-111.
47. Cohn JN, Levine TB, Olivari MT, et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic heart failure. N Engl J Med 1984, 311:819-823.
48. Kaye DM, Lefkovits J, Jennings GL, et al.: Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 1995, 26:1257-1263.
49. Bristow MR, Zelis R, Nuzzo R, et al.: Baseline and three month changes in systemic venous norepinephrine as predictors of clinical outcomes of the BEST trial. J Am Coll Cardiol 2001, 37:218A.
50. Heilbrunn SM, Shah P, Bristow MR, et al.: Baseline and threemonth changes in systemic venous norepinephrine as predictors of clinical outcomes of the best trial. J Am Coll Cardiol 2001, 37:218A.
51. Böhm M, Deutsch HJ, Hartmann D, et al.: Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997, 30:992-996.
52. Yamada S, Ohkura T, Uchida S, et al.: A sustained increase in b-adrenoceptors during long-term therapy with metoprolol and bisoprolol in patients with heart failure from idiopathic dilated cardiomyopathy. Life Sci 1996, 58:1737-1744.
53. Gilbert EM, Abraham WT, Olsen S, et al.: Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996, 94:2817-2825.
54. Böhm M, Ettelbruck S, Flesch M, et al.: b-adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy. Cardiovasc Res 1998, 40:146-155.
55. Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ: Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by b-adrenergic receptor stimulation and blockade. Circulation 1998, 98:1783-1789.
56. Newton GE, Parker JD: Acute effects of b1-selective and nonselective b-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996, 94:353-358.
57. Travill CM, Pugh S, Noble M: The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by b-adrenergic blockade. Clinical Therapeutics 1994, 16:783-792.
58. Galie N, Branzi A, Magnani G, et al.: Effects of enoximone alone and in combination with metoprolol on myocardial function and energetics in severe congestive heart failure: improvement in hemodynamic and metabolic profile. Cardiovasc Drugs Ther 1993, 7:337-347.
59. Tsvetkova TO, Farber DJ, Abraham WT, et al.: Comparative hemodynamic effects of milrinone and dobutamine in heart failure patients treated chronically with carvedilol [abstract 135]. J Card Fail 1998, 4:36.
60. Dage RC, Okerholm RA: Pharmacology and pharmacokinetics of enoximone. Cardiology 1990, 77(Suppl 3):2-13.
61. Edes I, Kiss E, Kitada Y: et al: Effects of levosimendan, a cardiac agent targeted to troponin C, on cardiac function and on phosphorylation and CA2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995, 77:107-113.
62. Francis SH, Noblett BD, Todd BW, et al.: Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol Pharmacol 1988, 34:506-517.
63. Baim DS, McDowell AV, Cherniles J, et al.: Evaluation of a new bipyridine inotropic agent, milrinoe, in patients with severe congestive heart failure. N Engl J Med 1983, 309:748-756.
64. Heiss HW, Hasenfuss G, Holubarsch C, et al.: Cardiac energetics after intravenous enoximone in idiopathic dilated cardiomyopathy. Am J Cardiol 1987, 60:53C.
65. Szabo BM, van Vedhuisen DJ, van Dijk RB, et al.: Hemodynamic and autonomic effects of intravenous saterinone in patients with chronic heart failure. J Cardiovasc Pharmacol 1997, 29:618-623.
66. Silke B, Hanratty CG, Riddell JG: Heart-rate variability effects of b-adrenoceptor agonists (xamoterol, prenalterol, and salbutamol) assessed nonlinearly with scatterplots and sequence methods. J Cardiovasc Pharmacol 1999, 33:859-867.
67. Lowes BD, Higginbotham M, Petrovich L, et al.: Low-dose enoximone improves exercise capacity in chronic heart failure. J Am Coll Cardiol 2000, 36:501-508.
68. Herrmann HC, Ruddy TD, Dec GW, et al.: Diastolic function in patients with severe heart failure: comparison of the effects of enoximone and nitroprusside. Circulation 1987, 75:1214-1221.
69. Haber HL, Simek CL, Gimple LW, et al.: Why do patients with congestive heart failure tolerate the initiation of b-blocker therapy? Circulation 1993, 88:1610-1619.
70. Newton GE, Parker JD: Acute effects of b 1-selective and nonselective b-adrenergic receptor blockade on cardiac sympathetic activity in congestive heart failure. Circulation 1996, 94:353-358.
71. Shakar SF, Abraham WT, Gilbert EM, et al.: Combined oral positive inotropic and b-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol 1998, 31:1336-1340.
72. Lowes BD, Simon MA, Tsvetkova TO, Bristow MR: Inotropes in the b-blocker era. Clin Cardiol 2000, 23(Suppl III):III11-III16.
73. Hall JA, Ferro A, Dickerson JE, Brown MJ: b adrenoreceptor subtype cross regulation in the human heart. Br Heart J 1993, 69:332-337.
74. Gilbert EM, Hershberger RE, Wiechmann RJ, et al.: Pharmacologic and hemodynamic effects of combined b-agonist stimulation and phosphodiesterase inhibition in the failing human heart. Chest 1995, 108:1524-1532.
75. Böhm M, Diet F, Kemkes B, Erdmann E: Enhancement of the effectiveness of milrinone to increase force of contraction by stimulation of cardiac b-adrenoceptors in the failing human heart. Klin Wochenschr 1988, 66:957-962.
76. Sigmund M, Jakob H, Becker H, et al.: Effects of metoprolol on myocardial b-adrenoceptors and Gia-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 1996, 51:127-132.